Moerae Matrix has initiated a lipopolysaccharide (LPS) challenge study of its MMI-0100 inhaled MAPKAP kinase 2 (MK2) inhibitor to evaluate its safety and tolerability in smokers, the company said. Moerae is developing MMI-0100 as a DPI for the treatment of idiopathic pulmonary fibrosis and other pulmonary diseases and has already conducted one Phase 1 study.
In that first ascending dose study, according to Moerae, 48 healthy subjects received 7 dose levels of MMI-0100 and experienced no serious adverse effects and was well tolerated.
Moerae Matrix Chief Medical Officer Bill Bradford commented, “The encouraging safety and tolerability results from the recently completed single ascending dose study coupled with the strong anti-inflammatory and anti-fibrotic activity observed in a variety of preclinical animal models provide a strong foundation for advancing MMI-0100 in the clinic. The now-ongoing LPS challenge study will inform the next steps as we move towards studying patients with pulmonary disease.”
Read the Moerae Matrix press release.
